Schwab Charles Investment Management Inc. raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 4.6% during the first quarter, Holdings Channel reports. The fund owned 5,131,359 shares of the biopharmaceutical company’s stock after buying an additional 227,978 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $279,044,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. American National Bank raised its position in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC increased its position in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the last quarter. Crestwood Advisors Group LLC bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at $116,000. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 60 shares during the last quarter. 69.79% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company (BMY) traded up 0.53% during midday trading on Friday, hitting $56.89. The company’s stock had a trading volume of 910,810 shares. The company has a market cap of $93.30 billion, a price-to-earnings ratio of 20.78 and a beta of 1.17. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $61.30. The company’s 50-day moving average is $55.82 and its 200 day moving average is $54.60.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter last year, the business posted $0.69 earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were given a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.76%. Bristol-Myers Squibb’s payout ratio is 56.73%.

ILLEGAL ACTIVITY WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/bristol-myers-squibb-company-bmy-shares-bought-by-schwab-charles-investment-management-inc.html.

Several equities analysts have recently weighed in on the company. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday. BidaskClub downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Vetr downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target for the company. in a report on Tuesday, July 25th. Leerink Swann reduced their price target on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, July 28th. Finally, William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $62.69.

In related news, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.